Kane Biotech Inc (TSE:KNE)
:KNE
Total Valuation
Kane Biotech has a market cap or net worth of C$5.46M. The enterprise value is C$6.38M.
Market CapC$5.46M
Enterprise ValueC$6.38M
Share Statistics
Kane Biotech has 181,846,560 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding181,846,560
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kane Biotech’s return on equity (ROE) is 1.86 and return on invested capital (ROIC) is -478.88%.
Return on Equity (ROE)1.86
Return on Assets (ROA)-1.21
Return on Invested Capital (ROIC)-478.88%
Return on Capital Employed (ROCE)-53.37
Revenue Per Employee65.03K
Profits Per Employee-98.78K
Employee Count32
Asset Turnover0.83
Inventory Turnover3.21
Valuation Ratios
The current PE Ratio of Kane Biotech is ―. Kane Biotech’s PEG ratio is 0.13.
PE Ratio―
PS Ratio7.08
PB Ratio-9.04
Price to Fair Value-9.04
Price to FCF-3.56
Price to Operating Cash Flow-1.68
PEG Ratio0.13
Income Statement
In the last 12 months, Kane Biotech had revenue of 2.08M and earned -3.02M in profits. Earnings per share was -0.02.
Revenue2.08M
Gross Profit872.10K
Operating Income-4.49M
Pretax Income-4.47M
Net Income-3.02M
EBITDA-3.71M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -2.99M and capital expenditures -98.99K, giving a free cash flow of -3.09M billion.
Operating Cash Flow-2.99M
Free Cash Flow-3.09M
Free Cash Flow per Share-0.02
Dividends & Yields
Kane Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.83
52-Week Price Change-70.00%
50-Day Moving Average0.04
200-Day Moving Average0.04
Relative Strength Index (RSI)35.77
Average Volume (3m)112.95K
Important Dates
Kane Biotech upcoming earnings date is May 21, 2026, TBA (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateMay 21, 2026
Ex-Dividend Date―
Financial Position
Kane Biotech as a current ratio of 0.43, with Debt / Equity ratio of -289.57%
Current Ratio0.43
Quick Ratio0.27
Debt to Market Cap0.10
Net Debt to EBITDA-0.52
Interest Coverage Ratio-8.24
Taxes
In the past 12 months, Kane Biotech has paid -1.31M in taxes.
Income Tax-1.31M
Effective Tax Rate0.29
Enterprise Valuation
Kane Biotech EV to EBITDA ratio is -4.49, with an EV/FCF ratio of -4.03.
EV to Sales8.01
EV to EBITDA-4.49
EV to Free Cash Flow-4.03
EV to Operating Cash Flow-4.05
Balance Sheet
Kane Biotech has C$939.06K in cash and marketable securities with C$2.30M in debt, giving a net cash position of -C$1.36M billion.
Cash & Marketable SecuritiesC$939.06K
Total DebtC$2.30M
Net Cash-C$1.36M
Net Cash Per Share>-C$0.01
Tangible Book Value Per Share-C$0.02
Margins
Gross margin is -22.90%, with operating margin of -215.96%, and net profit margin of -145.35%.
Gross Margin-22.90%
Operating Margin-215.96%
Pretax Margin-214.88%
Net Profit Margin-145.35%
EBITDA Margin-178.17%
EBIT Margin-188.66%
Analyst Forecast
The average price target for Kane Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―